SMARCB1 and urinary bladder cancer: Reduced levels of SNF5/BAF47 (it is encoded by the SAMRCB1) expression could potentially lead to heightened insusceptibility to primary medications like cisplatin and gemcitabine in bladder cancer cells [58].